SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention over the wait for the 80th overall-survival event in its Phase 3 REGAL AML trial and the companys quiet period; the last reported count was 78, and no new result is confirmed. Bulls view the prolonged wait as a possible sign of extended survival on GPS, while bears question the trial and disclosure timeline, and the selloff has fueled debate over whether market and options pressure or company-specific concerns are driving the move.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after Fridays selloff has dominated discussion, pushing back against widespread Black Monday crash fears. Bulls view the move as a relief rally or short squeeze, while skeptics call it a low-volume bull trap and question whether it will hold; some traders also speculate that Russia-related diesel and peace-talk headlines are helping sentiment.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp tech- and AI-linked selloff followed by a strong futures rebound, with traders split over whether the bounce signals recovery or is a short-covering rally that could fade. Crash warnings, including Black Monday talk, are competing with optimism ahead of major tech earnings.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor-sector selloff and volatile rebound, with traders debating whether the bounce marks a bottom or is a temporary rally. The bearish case centers on worries about AI spending, debt, inflation and Chinese competition, while dip buyers point to continued chip demand and the sectors oversold condition.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is drawing attention amid a sharp selloff across semiconductor and AI-linked stocks, with traders debating whether concerns about AI spending, inflation and broader market risk point to further weakness or an oversold pullback. Bulls point to Intels foundry prospects and upcoming earnings, while bears question its valuation and warn the selling may continue.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on lifileucel is driving attention: traders are weighing mature frontline melanoma results and early sarcoma responses as encouraging signs, while noting the small cohorts and need for confirmation in larger trials. The sharp pullback is widely viewed in the discussion as part of broader biotech and market weakness rather than a clear company-specific reaction.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep decline is drawing attention to staged IPO lockup expirations, which make more shares eligible for sale, alongside weakness across AI and semiconductor stocks. Traders are split between viewing the selloff as a buying opportunity and worrying that potential insider selling, high valuation and customer-concentration concerns could prolong pressure.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff across neocloud and AI-infrastructure stocks, driven by worries about debt, financing costs, and whether heavy data-center spending will pay off, is weighing on Nebius. Traders are divided: bears see more downside as the sector faces a valuation reset, while bulls argue Nebius is financially stronger than some peers and the pullback is overdone.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCIs steep selloff is drawing attention amid a broader pullback in AI and semiconductor stocks, with traders also focused on renewed governance and export-control concerns after a contractor pleaded guilty in a server-smuggling case. The debate centers on whether the decline is an overdone sector-driven drop or reflects company-specific risks ahead of earnings; bulls cite valuation and AI demand, while bears question management credibility and the outlook.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially the first Phase 1 azer-cel results in progressive MS, alongside BRIUMVI long-term and ENHANCE data; traders see the late-breaking oral slot as a notable event, but it does not establish that the results will be positive. Many are optimistic about the data and upcoming subcutaneous BRIUMVI readout, while others are frustrated by the share-price stagnation and treat buyout talk as speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AIM ETF Products Trust - AllianzIM U.S. Equity Buffer20 Jan ETF

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

JANW AIM ETF Products Trust - AllianzIM U.S. Large Cap Buffer20 Jan ETF

Fundamentals

Latest JANW News